Bruker completed the acquisition of ELITech from PAI Partners for $744m.

Bruker, an international life science research and diagnostics solutions provider, completed the acquisition of ELITech, a global manufacturer of in-vitro diagnostics, from PAI Partners, a private equity firm, for $774m. "We are very pleased to welcome ELITech to Bruker. The ELITech molecular diagnostics sample-to-answer platforms for viral infection and other esoteric MDx assays complement our MALDI Biotyper® platform for bacterial and fungal identification. The combined offerings establish Bruker as an innovative and growing infectious disease specialist in the in-vitro diagnostics (IVD) market,” Frank H. Laukien, Bruker President and CEO.